Table 1.

Anti-Tumor Activity of Mobocertinib (160mg/Day) in EGFRex20ins Mutation Positive NSCLC Cohorts

	Phase 1/2 Cohort (n = 28)	EXCLAIM Cohort (n = 96)	Platinum Pretreatment Patient Cohort (PPP) (n = 114)
Overall Response Rate (ORR) – no. (%) [95% CI]	12 (43) [24–63]	24 (25) [17–35]	32 (28) [20–37]
Median Duration of Response (mDOR) -months (95% CI)	13.9 (5.0 – not reached)	Non-estimable	17.5 (7.4–20.3)
Median Progression Free Survival (mPFS) – months (95% CI)	7.3 (4.4–15.6)	7.3 (5.5–9.1)	7.3 (5.5–9.2)
Median Overall Survival (mOS) – months (95% CI)	Not evaluated	Not Reached	24 (14.6–28.8)